Aleksandrs Zhavoronkov
Founder at InSilico Medicine Hong Kong Ltd.
Profile
Dr Alex Zhavoronkov is the CEO of Insilico Medicine, a Baltimore-based leader in next-generation artificial intelligence and blockchain technologies for drug discovery, biomarker development and ageing research.
He co-founded LongeVC and is the Head of its Advisory Board.
At Insilico, Alex pioneered generative adversarial networks and reinforcement learning techniques for generating novel molecular structures with the desired properties.
He set up the R&D centres in six countries, including Korea, Russia and Taiwan, and launched multiple biomarker initiatives, including YoungAI.
Next to advising for LongeVC, Alex is one of the Longevity Science Foundation's Visionary Board members.
Before founding Insilico Medicine, Alex worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, the Biogerontology Research Foundation, and YLabs.AI.
He also created AgeNet.net, a platform with contests, hackathons, and resources for ageing biomarker development competitions, and led the diversity.AI initiative.
Since 2012, he has published more than 80 peer-reviewed research papers and books, including "The Ageless Generation: How Biomedical Advances Will Transform the Global Economy." He is also the co-organiser of the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum at EMBO/Basel Life, one of Europe's most significant drug discovery industry events.
Dr Zhavoronkov holds two Bachelor's degrees from Queen's University, a Master's in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University.
Aleksandrs Zhavoronkov active positions
Companies | Position | Start |
---|---|---|
Biogerontology Research Foundation | Director/Board Member | 17/09/2009 |
InSilico Medicine Hong Kong Ltd.
InSilico Medicine Hong Kong Ltd. Information Technology ServicesTechnology Services InSilico Medicine Hong Kong Ltd. operates as bioinformatics company, which utilizes advances in genomics, big data analysis and deep learning for silico drug discovery and drug repurposing for aging and age-related diseases. The company was founded by Alex Zhavoronkov and is headquartered in Hong Kong. | Founder | - |
Deep Longevity Ltd.
Deep Longevity Ltd. Packaged SoftwareTechnology Services Deep Longevity Ltd. develops artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system and psychological levels. Its products include longevity cloud, recommendation engines, deep aging clocks and age metric reports. The company was founded in 2020 by Alex Zhavoronkov and is headquartered in San Diego, CA. | Chief Executive Officer | 01/01/2020 |
Insilico Medicine IP Ltd.
Insilico Medicine IP Ltd. BiotechnologyHealth Technology Insilico Medicine IP Ltd. engages in the investment of drug discovery and drug development through the deployment of new artificial intelligence technologies. The company was founded on June 21, 2019 and is headquartered in Hong Kong. | Chief Executive Officer | - |
Alliance For Artificial Intelligence In Healthcare
Alliance For Artificial Intelligence In Healthcare Packaged SoftwareTechnology Services The Alliance for Artificial Intelligence in Healthcare (AAIH) is an advocacy organization that aims to improve patient outcomes and minimize healthcare costs through the discovery, development, and delivery of better solutions. The private company is based in Long Island City, NY, and was founded by Brandon Allgood. The organization fosters creativity, collaboration, and knowledge sharing among its members, who come from diverse backgrounds in science, math, technology, and healthcare. AAIH is focusing on two primary practice areas in 2023: developing a comprehensive framework for digitizing IND and addressing core challenges in data accessibility through a real-world data registry. | Director/Board Member | - |
InSilico Medicine, Inc.
InSilico Medicine, Inc. Packaged SoftwareTechnology Services Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014. | Founder | 01/01/2014 |
Insilico Medicine Cayman TopCo
Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong. | Chief Executive Officer | 19/11/2018 |
LongeVC
LongeVC Investment ManagersFinance LongeVC is a venture capital firm, founded in 2020 by Garri Zmudze, Ilya Suharenko, Sergey Jakimov. The firm is headquartered in Lugano, Switzerland. | Founder | 01/01/2016 |
Former positions of Aleksandrs Zhavoronkov
Companies | Position | End |
---|---|---|
Colby Pharmaceutical Co.
Colby Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions. Colby's lead drugs have unique mechanisms of action and target specific pathways. The company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs. | Corporate Officer/Principal | 01/01/2009 |
░░░░░░░ ░░░░ | ░░░░░░░░░ | - |
░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░ ░ ░░░░░░░░░ | - |
Training of Aleksandrs Zhavoronkov
Queen's University | Undergraduate Degree |
The Johns Hopkins University | Graduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 12 |
---|---|
ATI Technologies ULC
ATI Technologies ULC SemiconductorsElectronic Technology ATI Technologies, Inc. designs, makes and, sells graphics accelerators and multimedia solutions. It offers visual and graphics processors for displaying images on personal computer monitors. It also supplies graphics, video and, multimedia products for desktop, workstation & notebook personal computers, digital televisions, cell phones, and game consoles. The company sells its products through personal computer original equipment manufacturers, system integrators, add-in board manufacturers, retail stores & consumer electronics manufacturers in North America, Europe and Asia-Pacific. The firm was founded by Kwok Yuen Ho in 1985 and is located in Markham, Canada. | Electronic Technology |
Moscow State University | Consumer Services |
Colby Pharmaceutical Co.
Colby Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions. Colby's lead drugs have unique mechanisms of action and target specific pathways. The company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs. | Health Technology |
Mediox, Inc. | |
Biogerontology Research Foundation | |
InSilico Medicine Hong Kong Ltd.
InSilico Medicine Hong Kong Ltd. Information Technology ServicesTechnology Services InSilico Medicine Hong Kong Ltd. operates as bioinformatics company, which utilizes advances in genomics, big data analysis and deep learning for silico drug discovery and drug repurposing for aging and age-related diseases. The company was founded by Alex Zhavoronkov and is headquartered in Hong Kong. | Technology Services |
InSilico Medicine, Inc.
InSilico Medicine, Inc. Packaged SoftwareTechnology Services Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014. | Technology Services |
Insilico Medicine Cayman TopCo
Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong. | Commercial Services |
Alliance For Artificial Intelligence In Healthcare
Alliance For Artificial Intelligence In Healthcare Packaged SoftwareTechnology Services The Alliance for Artificial Intelligence in Healthcare (AAIH) is an advocacy organization that aims to improve patient outcomes and minimize healthcare costs through the discovery, development, and delivery of better solutions. The private company is based in Long Island City, NY, and was founded by Brandon Allgood. The organization fosters creativity, collaboration, and knowledge sharing among its members, who come from diverse backgrounds in science, math, technology, and healthcare. AAIH is focusing on two primary practice areas in 2023: developing a comprehensive framework for digitizing IND and addressing core challenges in data accessibility through a real-world data registry. | Technology Services |
Deep Longevity Ltd.
Deep Longevity Ltd. Packaged SoftwareTechnology Services Deep Longevity Ltd. develops artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system and psychological levels. Its products include longevity cloud, recommendation engines, deep aging clocks and age metric reports. The company was founded in 2020 by Alex Zhavoronkov and is headquartered in San Diego, CA. | Technology Services |
LongeVC
LongeVC Investment ManagersFinance LongeVC is a venture capital firm, founded in 2020 by Garri Zmudze, Ilya Suharenko, Sergey Jakimov. The firm is headquartered in Lugano, Switzerland. | Finance |
Insilico Medicine IP Ltd.
Insilico Medicine IP Ltd. BiotechnologyHealth Technology Insilico Medicine IP Ltd. engages in the investment of drug discovery and drug development through the deployment of new artificial intelligence technologies. The company was founded on June 21, 2019 and is headquartered in Hong Kong. | Health Technology |
- Stock Market
- Insiders
- Aleksandrs Zhavoronkov